Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Thermosensitive Liposome Formulation with Topotecan and Doxorubicin as Drug Payload for Delivery Coupled with High Intensity Focused Ultrasound

Raafay Mehmood, Faran Rashid and Zainab Mansoor

The delivery of cancer drugs such as topotecan and doxorubicin poses risks such as off target tissue interactions and systemic toxicity. The use of thermosensitive liposomes provides a targeted manner to deliver such drugs with minimal risk, since drug release occurs upon administration of hyperthermia at the target site, such as focused ultrasound. Topotecan and doxorubicin were tested for their suitability in the design of a thermosensitive liposome formulation, using the film hydration method to produce thermosensitive liposomes. The lipid film was hydrated with ammonium sulphate buffer (300 mM pH 4.0), with subsequent gas extrusion. The exterior of the liposomes was adjusted to pH 7.4 with buffer followed by drug loading by incubation at 38°C. Differential scanning calorimetry, dynamic light scattering, and fluorescence measurements were carried out as characteristic tests. Thermosensitive liposomes with a TM of 46°C and an approximate diameter of 100nm were produced, while releasing their drug payload between 39°C-42°C. Doxorubicin ’ s self-quenching properties prevented accurate release profile fluorescence readings. Therefore, topotecan is a better suited model drug for the design and optimization of a thermosensitive liposome formulation compared to doxorubicin, reducing the risk of drug leakage outside of target site. Thermosensitive liposomes were successfully formulated with topotecan and doxorubicin.